Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier JS; Khanani AM; Quezada Ruiz C; Basu K; Ferrone PJ; Brittain C; Figueroa MS; Lin H; Holz FG; Patel V; Lai TYY; Silverman D; Regillo C; Swaminathan B; Viola F; Cheung CMG; Wong TY

doi:10.1016/s0140-6736(22)00010-1

← Today's brief

Study

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier JS et al. · Lancet (London, England) · Monday, January 24, 2022

Funding Not reported

Source

Heier JS et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet (London, England). Monday, January 24, 2022.
doi:10.1016/s0140-6736(22)00010-1Read original ↗

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.